Impaired circulating myeloid DCs from myeloma patients

被引:19
作者
Do, TH
Johnsen, HE
Kjærsgaard, E
Taaning, E
Svane, IM [1 ]
机构
[1] Univ Copenhagen, Herlev Hosp, Dept Haematol, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Clin Immunol, DK-2730 Herlev, Denmark
关键词
dendritic cells; whole blood; myeloma; quantitation; phenotyping;
D O I
10.1080/14653240410006004
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background In clinical trials, cancer patients have received immunotherapy based on DCs generated from leukapheresed blood. It would therefore be an advantage to be able to measure blood levels and estimate the phenotype of DC before leukapheresis, to estimate the yield required for preparation of vaccines, or ex vivo stimulation of T cells for adoptive immunotherapy. Methods Recently, circulating lineage negative (Lin(-)) myeloid DC cells and their precursors have been identified by flow cytometry. We apply this strategy to the screening of blood samples from patients with multiple myeloma, in an attempt to characterize and quantitate the subset. By a direct flow cytometry approach, the blood levels of circulating lineage (CD3, CD19, CD14) negative, CD33(+) (+), HLA-DR+ cells were estimated before and following ex vivo cell differentiation, and phenotyped by MAbs with specificity against HLA-DR, HLA-ABC, CD1a, CD11c, CD33, CD40, CD49d, CD49e, CD54, CD80, CD83, and CD86. Results This study demonstrated that multiple myeloma patients have a 50% reduced blood level of Lin(-), CD33(+) (+), HLA-DR+ myeloid DC, but a DC-precursor level within normal range. Furthermore, GM-CSF and IL-4 ex vivo stimulated DCs demonstrated an impaired upregulation of the co-stimulatory molecule CD80 and the adhesion molecule CD54. Discussion These results may have clinical implications as a predictor for yield and functionality of the harvested DCs to be used in vaccination of myeloma patients.
引用
收藏
页码:196 / 203
页数:8
相关论文
共 31 条
[1]  
Almand B, 2000, CLIN CANCER RES, V6, P1755
[2]   Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer [J].
Almand, B ;
Clark, JI ;
Nikitina, E ;
van Beynen, J ;
English, NR ;
Knight, SC ;
Carbone, DP ;
Gabrilovich, DI .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :678-689
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10 [J].
Brown, RD ;
Pope, B ;
Murray, A ;
Esdale, W ;
Sze, DM ;
Gibson, J ;
Ho, PJ ;
Hart, D ;
Joshua, D .
BLOOD, 2001, 98 (10) :2992-2998
[5]   DCs and peripheral T cell tolerance [J].
Fazekas de St Groth, B .
SEMINARS IN IMMUNOLOGY, 2001, 13 (05) :311-321
[6]   Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation [J].
Fearnley, DB ;
Whyte, LF ;
Carnoutsos, SA ;
Cook, AH ;
Hart, DNJ .
BLOOD, 1999, 93 (02) :728-736
[7]  
Geiger JD, 2001, CANCER RES, V61, P8513
[8]   Dendritic cells:: multi-lineal and multi-functional [J].
Grabbe, S ;
Kämpgen, E ;
Schuler, G .
IMMUNOLOGY TODAY, 2000, 21 (09) :431-433
[9]   Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients [J].
Hasebe, H ;
Nagayama, H ;
Sato, K ;
Enomoto, M ;
Takeda, Y ;
Takahashi, TA ;
Hasumi, K ;
Eriguchi, M .
BIOMEDICINE & PHARMACOTHERAPY, 2000, 54 (06) :291-298
[10]   Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines [J].
Ho, CSK ;
Munster, D ;
Pyke, CM ;
Hart, DNJ ;
López, JA .
BLOOD, 2002, 99 (08) :2897-2904